Skip to main content

Macquarie Group Ltd

SEC CIK
0001418333
Latest filing
Aug 14, 2026

HALO holding history

Halozyme Therapeutics, Inc. in every 13F filed by Macquarie Group Ltd, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

HALO overviewAll 13F holders of HALOFull Q2 2026 holdings

Shares (Q4 2025)
0
Sold out in Q4 2025
Value
$0
% of portfolio
0.0%
Quarters held
19
Since Q1 2021
Holdings of HALO by Macquarie Group Ltd, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q4 20250$00.0%−1,546,185−100.0%Sold outHolders
Q3 20251,546,185$113.4M0.1%−537,207−25.8%ReducedHolders
Q2 20252,083,392$108.4M0.1%−590,881−22.1%ReducedHolders
Q1 20252,674,273$170.6M0.2%−231,212−8.0%ReducedHolders
Q4 20242,905,485$138.9M0.2%−105,340−3.5%ReducedHolders
Q3 20243,010,825$172.3M0.2%−66,702−2.2%ReducedHolders
Q2 20243,077,527$161.1M0.2%+86,402+2.9%AddedHolders
Q1 20242,991,125$121.7M0.1%−291,515−8.9%ReducedHolders
Q4 20233,282,640$121.3M0.1%−161,550−4.7%ReducedHolders
Q3 20233,444,190$131.6M0.2%+134,835+4.1%AddedHolders
Q2 20233,309,355$119.4M0.1%+108,874+3.4%AddedHolders
Q1 20233,200,481$122.2M0.1%+595,220+22.8%AddedHolders
Q4 20222,605,261$148.2M0.2%+50,294+2.0%AddedHolders
Q3 20222,554,967$101.1M0.1%+34,436+1.4%AddedHolders
Q2 20222,520,531$110.9M0.1%+45,885+1.9%AddedHolders
Q1 20222,474,646$98.7M0.1%−598,310−19.5%ReducedHolders
Q4 20213,072,956$123.6M0.1%+80,889+2.7%AddedHolders
Q3 20212,992,067$121.7M0.1%+50,129+1.7%AddedHolders
Q2 20212,941,938$133.6M0.1%+731,878+33.1%AddedHolders
Q1 20212,210,060$92.1M0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.